Clinical Trial Update: Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Copanlisib in combination with Rituximab in relapsed indolent B-cell non-Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• Rituxan (rituximab)

Snippet

Sponsor: Bayer | Conditions: Lymphoma,Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2022-01-04